For the primary endpoint, retatrutide lowered A1C by an average of 1.7% to 2.0% across doses at 40 weeks in TRANSCEND-T2D-1 Participants taking retatrut...
Ractigen Therapeutics, a pioneering clinical-stage biotechnology company developing innovative small activating RNA (saRNA) therapeutics, announced that ...
Congruence Therapeutics announced that the first participant has been dosed in its Phase 1/1b clinical trial evaluating CGX-926, an oral small-mole...
Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at comme...
Primary endpoint met in Phase 3 TALAPRO-3 study demonstrating a statistically significant and clinically meaningful reduction in risk of disease prog...
— $9M Second Phase of CDMO Investment Builds on 2025 $6M Expansion, Funding Facility Upgrades and Increased Capacity for Suppository, Semi-Solid,...
Reimagining early-stage drug discovery leveraging NVIDIA BioNeMo Framework -- Persistent Systems (BSE: 533179) (NSE: PERS...
Highly potent drugs now account for over 30% of the global pipeline, with more than 1,000 molecules in development — Axplora’s investments in...
YolTech Therapeutics, a late clinical-stage biotechnology company developing in vivo gene-editing therapies, today announced that the U.S. Food and Drug ...
23andMe, a leading consumer genetics and research organization and nonprofit affiliate of the 23andMe Research Institute, today announced the launch of a...
Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often e...
iXCells Biotechnologies USA, Inc. (“iXCells”), a leading provider of human cell-based solutions and custom iPSC services, announced the d...
As the antibody–drug conjugate (ADC) landscape rapidly evolves, the industry is moving beyond traditional cytotoxic payloads and antibody-first devel...
New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform ...
© 2026 Biopharma Boardroom. All Rights Reserved.
